NDLI: Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Please wait, while we are loading the content...

Low flucloxacillin concentrations in a patient with central nervous system infection: the need for plasma and cerebrospinal fluid drug monitoring in the ICU.

Use of propranolol for hypersexual behavior in an adolescent with autism.

Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study.

Effect of tumor necrosis factor- inhibitors on drug-induced pancreatitis in inflammatory bowel disease.

Histamine-2-receptor antagonist administration and gastrointestinal bleeding when used for stress ulcer prophylaxis in patients with severe sepsis or septic shock.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Clinical and economic impact of a quality improvement initiative to enhance early recognition and treatment of sepsis.

Energy drink-induced acute kidney injury.

Improvement of a woman's alcohol-related dementia via off-label memantine treatment: a 16-month clinical observation.

The prevention of contrast-induced nephropathy.

Successful treatment of ventriculostomy-associated meningitis caused by multidrug resistant coagulase-negative Staphylococcus epidermidis using low-volume intrathecal daptomycin and loading strategy.

Bone health evaluation in a veteran population: a need for the Fracture Risk Assessment Tool (FRAX).

New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate.

Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.

Impact of medication reconciliation and review on clinical outcomes.

Interventions to reduce medication errors in pediatric intensive care.

Extended-release hydrocodone: the devil in disguise or just misunderstood?

Year: 2014 Volume: 48 Issue: 6

Year: 2014 Volume: 48 Issue: 5

Year: 2014 Volume: 48 Issue: 4

Year: 2014 Volume: 48 Issue: 3

Year: 2014 Volume: 48 Issue: 2

Year: 2014 Volume: 48 Issue: 1

Year: 2013 Volume: 47

Year: 2012 Volume: 46

Year: 2011 Volume: 45

Year: 2010 Volume: 44

Year: 2009 Volume: 43

Year: 2008 Volume: 42

Year: 2007 Volume: 41

Year: 2003 Volume: 37

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Eiland, Lea S. Bell, Edward A. Erramouspe, John
Description	Country affiliation: United States Author Affiliation: Eiland LS ( Auburn University Harrison School of Pharmacy, Huntsville, AL, USA eilanls@auburn.edu.); Bell EA ( Drake University College of Pharmacy, Des Moines, IA, USA.); Erramouspe J ( Idaho State University College of Pharmacy, Pocatello, ID, USA.)
Abstract	OBJECTIVE: To review the association of priapism with stimulant medications and atomoxetine commonly used in the treatment of attention-deficit/hyperactivity disorder (ADHD). DATA SOURCES: A comprehensive literature search was conducted through PubMed (1966-May 15, 2014) using the search terms priapism, methylphenidate, amphetamine, atomoxetine, attention-deficit disorder with hyperactivity, and pediatrics. Google Scholar, Scopus, and the Food and Drug Administration (FDA) Web site were also searched. References from identified literature were also reviewed. STUDY SELECTION AND DATA EXTRACTION: All identified literature focused on ADHD treatment. Literature regarding priapism caused by methylphenidate, amphetamines, and atomoxetine were included. DATA SYNTHESIS: Stimulant medications and atomoxetine have been linked to the occurrence of priapism in children. Specifically, methylphenidate has been implicated in a recent FDA safety announcement warning as a result of 15 case reports (mean age = 12.5 years), and thus, the drug label and medication guides have been updated to reflect this concern. Prolonged erections and priapism occurred with immediate- and long-acting products, dose increases, and drug withdrawal periods. Priapism has also occurred in 4 patients taking amphetamines and one 11-year-old patient taking atomoxetine for ADHD. CONCLUSIONS: Priapism has been associated with stimulants, amphetamines, and atomoxetine use for ADHD in children. Providers and health care practitioners should educate male patients prescribed these ADHD medications as well as caregivers regarding the signs, symptoms, and complications with priapism. Discontinuation and evaluation of the medication is warranted if this adverse drug reaction occurs. Depending on the priapism subtype, other products may be initiated or medications not associated with priapism may be utilized.
File Format	HTM / HTML
ISSN	10600280
Issue Number	10
Volume Number	48
e-ISSN	15426270
Journal	Annals of Pharmacotherapy
Language	English
Publisher	SAGE Publications
Publisher Date	2014-10-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmaceutical Science Adrenergic Uptake Inhibitors Adverse Effects Attention Deficit Disorder With Hyperactivity Drug Therapy Central Nervous System Stimulants Priapism Chemically Induced Propylamines Amphetamines Atomoxetine Hydrochloride Child Humans Male Methylphenidate Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.

Clinical practice: Adult attention deficit-hyperactivity disorder.

Attention deficit hyperactivity disorder: part III.

Adult Attention Deficit–Hyperactivity Disorder

Attention deficit hyperactivity disorder in adults.

Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.

Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Similar Documents

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.

Clinical practice: Adult attention deficit-hyperactivity disorder.

Attention deficit hyperactivity disorder: part III.

Adult Attention Deficit–Hyperactivity Disorder

Attention deficit hyperactivity disorder in adults.

Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.

Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.